ArticleJournal of hepatocellular carcinoma2025
Prognostic Significance and Mechanistic Insights of Rutin-Related Ferroptosis Gene Signature in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to elucidate the anti-tumor properties of rutin and its specific molecular mechanisms for inhibiting hepatocellular carcinoma (HCC) through the ferroptosis. Methods: The effects of rutin on HuH-7 cell proliferation, migration, invasion, and cell cycle progression were evaluated through in vitro experiments. By integrating bioinformatics analysis and network pharmacology, potential ferroptosis targets influenced by rutin in HCC were identified from the TCGA-LIHC database. A prognosis-related risk-scoring model was constructed and validated in the GEO14520 cohort and ICGC-LIRI-JP. Samples were categorized into high-risk and low-risk groups based on their scores. Enriched pathways within these different risk groups were explored using Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA). Additionally, key targets of rutin-related ferroptosis in HCC cells were investigated through single-cell analysis and molecular docking studies. Results: Rutin inhibited the proliferation, invasion, migration, and cell cycle progression of HCC cells in a dose-dependent manner. We constructed a risk model comprising five ferroptosis-related targets of rutin (FRTs-R): ACACA, AKR1C3, ALDH2, AR, and CDK1. This prognostic model was validated in the GEO14520 and ICGC datasets, revealing that the low-risk group had a better prognosis than the high-risk group. Furthermore, lipid metabolism pathway activity was up-regulated in the low-risk group. Single-cell analysis indicated specific expression of AKR1C3 in HCC cells, while molecular docking analysis showed that, among the five potential targets, AKR1C3 demonstrated the most stable binding affinity to rutin. Conclusion: Our findings suggest that rutin may modulate ferroptosis in HCC, with rutin associated ferroptosis genes implicated in disease biology; moreover, the proposed risk scoring model shows promising prognostic utility in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.